Bromodomain-containing protein 4 (BRD4)是组蛋白乙酰化的阅读器，与多种疾病相关。为了研究BRD4在食管鳞癌（ESCC）中的表达水平、预后价值及其与免疫浸润的关系。该研究包括来自癌症基因组图谱（TCGA）数据库的94名ESCC患者和南通大学附属医院2的179名ESCC患者。通过免疫组化检测组织微阵列中蛋白的表达水平。预后因素通过Kaplan-Meier曲线和单变量和多元Cox回归进行分析。使用ESTIMATE网站计算基质、免疫和ESTIMATE分数。使用CIBERSORT计算免疫浸润的丰度。使用Spearman和Phi系数进行相关性分析。使用TIDE算法预测免疫检查点阻断的治疗反应。BRD4在ESCC中上调，高BRD4表达水平与不良临床病理特征和预后相关。此外，BRD4高表达组的单核细胞计数、全身炎症免疫指数、血小板/淋巴细胞比率和单核细胞/淋巴细胞比率均高于低表达组。最后，我们发现BRD4表达水平与免疫浸润相关，并且与CD8 + T细胞浸润呈负相关。高TIDE分数在BRD4高表达组中高于低表达组。BRD4与ESCC的不良预后和免疫浸润相关，并可能成为预后和免疫治疗应用的潜在生物标志物。©2023作者。

Bromodomain-containing protein 4 (BRD4) is a reader of histone acetylation and is associated with a variety of diseases.To investigate the expression level of BRD4 in esophageal squamous cell carcinoma (ESCC), its prognostic value and its relationship with immune infiltration.The study included 94 ESCC patients from The Cancer Genome Atlas (TCGA) database and 179 ESCC patients from Affiliated Hospital 2 of Nantong University. The expression levels of proteins in tissue microarray were detected by immunohistochemistry. The prognostic factors were analyzed by Kaplan-Meier curve and univariate and multivariate cox regression. The ESTIMATE website was used to calculate the stromal, immune and ESTIMATE score. CIBERSORT was used to calculate the abundance of immune infiltrates. Spearman and Phi coefficient were used for correlation analysis. The TIDE algorithm was used to predict treatment response to immune checkpoint blockade.BRD4 is up-regulated in ESCC, and high BRD4 expression level is associated with poor prognosis and adverse clinicopathological features. In addition, the monocyte count, systemic inflammatory-immunologic index, platelet-lymphocyte ratio, and monocyte-lymphocyte ratio in the BRD4 high expression level group were higher than in the low expression level group. Finally, we found that BRD4 expression level correlated with immune infiltration and that it was inversely correlated with infiltration of CD8 + T cells. Higher TIDE scores in the BRD4 high expression group than in the low expression group.BRD4 is associated with poor prognosis and immune infiltration in ESCC, and may be a potential biomarker for prognosis and immunotherapy application.© 2023. The Author(s).